Doxorubicin (DOX) is a potent antineoplastic drug used to treat many types of human tumor. The long-term adverse effect is cardiomyopathy. Chromium is an essential trace element mostly used to regulate glucose levels and enhance the response to insulin, especially in diabetes. Current study aimed to evaluate the cardioprotective effect of chromium picolinate against doxorubicin-induced cardiotoxicity in 28 male rats divided into four groups. Group I (Control group): received distilled water orally for 8 days. Group II (Doxorubicin group): received distilled water orally for 7 days, followed by a single doxorubicin dose (25 mg/kg) intraperitoneally. Group III (Chromium 2 mg): received chromium picolinate at a dose (2 mg /kg) orally for 7 days, followed by a single doxorubicin dose (25 mg/kg) intraperitoneally. Group IV (Chromium 4 mg): received chromium picolinate at a dose (4 mg /kg) orally for 7 days, followed by a single doxorubicin dose (25 mg/kg) intraperitoneally. Levels of lactate dehydrogenase (LDH) and serum troponin were assessed in the sera of all groups by ELISA technique while the cardiac homogenate used to assess malondialdehyde (MDA) by ELISA technique and superoxide dismutase (SOD) by RT-qPCR method and the results indicated that the co- administration of chromium picolinate at dose (2mg/kg) and (4mg/kg) caused a significant decrease in cardiac LDH and MDA and significant elevation in SOD level in groups III and IV compared to group II This current research indicated that Chromium picolinate have a potential role in reducing cardiac injury and oxidative stress in patients treated with doxorubicin.
